BioStem Technologies (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. Gorrell brings over two decades of experience advising healthcare organizations on regulatory, governance, and growth initiatives, and will oversee the company's legal and compliance functions, including the integration of Medical Affairs into its compliance framework.
Gorrell most recently served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, Florida, where she was a member of the Executive Team and led legal strategy across a complex healthcare enterprise. Prior to that, she was General Counsel and Compliance Officer for AdvancedMD, a national healthcare IT company, and held in-house roles at Intermountain Healthcare and Providence Health & Services/Swedish Health Services. Her background includes deep expertise in health law, regulatory affairs, transactional matters, compliance, governance, and risk management.
Chairman and CEO Jason Matuszewski highlighted the strategic importance of the appointment, stating that Gorrell's leadership will support the company's continued scaling while reinforcing its foundation of integrity and compliance, especially as BioStem progresses toward a Nasdaq uplisting. The company currently trades on the OTC market under the ticker BSEM.
BioStem Technologies develops, manufactures, and commercializes advanced allograft solutions derived from perinatal tissue, leveraging proprietary processing technologies including BioRetain, CryoTek, and SteriTek to preserve the natural properties of tissues for clinical use. Its product portfolio includes brands such as Neox, Clarix, VENDAJE, and American Amnion. The company's quality management system is accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and current Good Manufacturing Processes.
The appointment comes at a pivotal time for the company as it expands its commercial footprint and clinical research initiatives. Gorrell's experience in guiding organizations through complex regulatory environments will be critical as BioStem navigates the requirements for a Nasdaq listing and continues to scale its operations. Her role will also involve strengthening enterprise governance and ensuring that legal and compliance functions evolve alongside the business.
Gorrell holds a JD with Honors, with a concentration in Health Law, from the University of Washington School of Law, and a Bachelor of Arts with Honors in Political Science from the University of Utah. She expressed enthusiasm for joining BioStem at this stage of its growth, emphasizing the importance of sustainable growth and strong governance.
For more information about BioStem Technologies, visit their website at www.biostemtechnologies.com. The latest news and updates about the company are available in their newsroom at https://tinyurl.com/bsemnewsroom.
